TWI878541B - 抗cldn18.2抗體及其診斷用途 - Google Patents

抗cldn18.2抗體及其診斷用途 Download PDF

Info

Publication number
TWI878541B
TWI878541B TW110118625A TW110118625A TWI878541B TW I878541 B TWI878541 B TW I878541B TW 110118625 A TW110118625 A TW 110118625A TW 110118625 A TW110118625 A TW 110118625A TW I878541 B TWI878541 B TW I878541B
Authority
TW
Taiwan
Prior art keywords
antibody
cancer
antigen
seq
amino acid
Prior art date
Application number
TW110118625A
Other languages
English (en)
Chinese (zh)
Other versions
TW202212360A (zh
Inventor
雪明 錢
姚新來
郭歡歡
李紅俊
怡 顧
Original Assignee
中國大陸商蘇州創勝醫藥集團有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中國大陸商蘇州創勝醫藥集團有限公司 filed Critical 中國大陸商蘇州創勝醫藥集團有限公司
Publication of TW202212360A publication Critical patent/TW202212360A/zh
Application granted granted Critical
Publication of TWI878541B publication Critical patent/TWI878541B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW110118625A 2020-05-25 2021-05-24 抗cldn18.2抗體及其診斷用途 TWI878541B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020092092 2020-05-25
WOPCT/CN2020/092092 2020-05-25

Publications (2)

Publication Number Publication Date
TW202212360A TW202212360A (zh) 2022-04-01
TWI878541B true TWI878541B (zh) 2025-04-01

Family

ID=78745623

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110118625A TWI878541B (zh) 2020-05-25 2021-05-24 抗cldn18.2抗體及其診斷用途

Country Status (10)

Country Link
US (1) US20230331836A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157885A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023527937A (cg-RX-API-DMAC7.html)
KR (1) KR20230016212A (cg-RX-API-DMAC7.html)
CN (1) CN115836090A (cg-RX-API-DMAC7.html)
AU (1) AU2021279777A1 (cg-RX-API-DMAC7.html)
CA (1) CA3184008A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022014896A (cg-RX-API-DMAC7.html)
TW (1) TWI878541B (cg-RX-API-DMAC7.html)
WO (1) WO2021238831A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4349371A4 (en) 2021-06-02 2025-06-25 Bio-Thera Solutions, Ltd. DRUG CONJUGATE AND USE THEREOF
CN114539410B (zh) * 2022-03-15 2023-09-05 苏州量化细胞生物科技有限公司 Cldn18.2结合抗体、探针及在cldn18.2表达细胞的单细胞测序中的应用
WO2023196882A1 (en) * 2022-04-06 2023-10-12 Zai Lab (Us) Llc Claudin 18.2 immunohistochemistry assay and use thereof
CN114428174B (zh) * 2022-04-07 2022-07-08 北京肿瘤医院(北京大学肿瘤医院) 一种胃癌预后生物标志物及其应用
WO2024199673A1 (en) * 2023-03-31 2024-10-03 Università Degli Studi Di Verona Methods for predicting and improving therapeutic efficacy of cancer treatments and methods for cancer prognosis
WO2024211459A1 (en) * 2023-04-04 2024-10-10 Zai Lab (Shanghai) Co., Ltd Use of anti-claudin antibody for cancer treatment based on certain biomarkers
CN121399468A (zh) * 2023-05-08 2026-01-23 安捷伦科技有限公司 诊断和治疗癌症的免疫组织化学(ihc)方案和方法 - 密封蛋白18.2
KR20260022335A (ko) * 2023-06-03 2026-02-19 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 암의 치료를 위한 클라우딘 18.2 길항제를 포함하는 조합 요법
WO2024250437A1 (en) * 2023-06-08 2024-12-12 Antengene (Hangzhou) Biologics Co., Ltd. Anti-cldn18.2 antibodies and diagnostic uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110862454A (zh) * 2018-08-27 2020-03-06 南京圣和药业股份有限公司 一种抗Claudin18_2抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
ES2699753T3 (es) * 2014-01-29 2019-02-12 Biontech Ag Mimótopos peptídicos de claudina 18.2 y sus usos
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
CA3087423A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CN116178554B (zh) * 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
CN110606891B (zh) * 2018-06-17 2022-12-06 上海健信生物医药科技有限公司 一种针对人cldn18.2的抗体分子,抗原结合片段及其医药用途
JP7401538B2 (ja) * 2018-10-22 2023-12-19 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗cldn18.2抗体およびその使用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110862454A (zh) * 2018-08-27 2020-03-06 南京圣和药业股份有限公司 一种抗Claudin18_2抗体及其应用

Also Published As

Publication number Publication date
KR20230016212A (ko) 2023-02-01
EP4157885A4 (en) 2024-07-10
AU2021279777A1 (en) 2022-12-08
TW202212360A (zh) 2022-04-01
MX2022014896A (es) 2023-01-04
CN115836090A (zh) 2023-03-21
WO2021238831A1 (en) 2021-12-02
CA3184008A1 (en) 2021-12-02
US20230331836A1 (en) 2023-10-19
EP4157885A1 (en) 2023-04-05
JP2023527937A (ja) 2023-06-30

Similar Documents

Publication Publication Date Title
US20230331836A1 (en) Anti-cldn18.2 antibodies and diagnostic uses thereof
KR102781536B1 (ko) 항-4-1bb 항체 및 이의 용도
JP2018029605A (ja) 抗葉酸受容体アルファ抗体およびその使用
CN120365432A (zh) 双特异性抗体
WO2016171242A1 (ja) Epha2の検出
CN110139874B (zh) 抗ceacam6抗体及其使用方法
KR20230146591A (ko) 신규 항pad4 항체
CN118772279B (zh) 抗FGFR2b抗体或其抗原结合片段及其用途
CN104837867B (zh) 特异性结合tm4sf5蛋白的新型单克隆抗体及其应用
JPWO2016171107A1 (ja) Fgfr2の検出
JP7668013B2 (ja) Alk2/acvr1の細胞外領域を認識する抗体
TWI782000B (zh) 抗gpr20抗體、其製造方法及其應用
RU2850336C1 (ru) Антитела против клаудина 18.2 и их диагностическое применение
HK40089087A (en) Anti-cldn18.2 antibodies and diagnostic uses thereof
WO2024250437A1 (en) Anti-cldn18.2 antibodies and diagnostic uses thereof
HK40123863A (en) Anti-cldn18.2 antibodies and diagnostic uses thereof
WO2025117639A9 (en) Antibodies and methods for ptk7 detection
HK40013436A (en) Anti-gpr20 antibody